Weight loss tends to plateau after the first year
Therefore, the changes in the gut microbiota after a single injection of GLP-1RA seem to reflect the original effects of GLP-1RA more clearly than the changes in the gut microbiota after chronic administration
Developed to treat symptoms of type 2 diabetes, Ozempic (semaglutide) was licensed for medical use in 2017 by Novo Nordisk
Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: A pilot study
Ideal timing for testing: Before starting your GLP-1 medication (baseline) 4-6 weeks after starting treatment After any dose increase Quarterly during stable dosing Immediately if warning symptoms appear People at higher risk for electrolyte problems include those over 65, anyone with kidney disease, heart failure patients, people taking diuretics, and anyone with persistent GI symptoms lasting beyond the first 8-12 weeks of treatment
These are important results